

# A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

NCT06338995

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 3
<b>Sponsor</b>	Eli Lilly and Company
<b>Enrollment</b>	510 participants

## Key Eligibility Criteria

---

### Inclusion (8)

- Physician-diagnosed chronic rhinosinusitis (CRS) with bilateral nasal polyps (NP).
- Prior treatment with systemic corticosteroids (SCS) within the last 2 years (or a medical contraindication or intolerance to SCS), prior surgery for NP, or both.
- Endoscopic bilateral NPS score of at least 5 out of 8, with a minimum score of 2 in each nasal cavity performed at screening and baseline.
- Ongoing symptoms for at least 8 weeks prior to study entry (screening), including:
- Nasal congestion with moderate or severe symptom severity (score 2 or 3) at screening and a weekly average severity score of at least 1 (range 0 to 3) at randomization, and
- ... and 3 more (see full listing online)

### Exclusion (21)

- Have received a dose of lebrikizumab.
- Have received treatment with any rescue medication and/or have the need for surgery for NP during screening and/or run-in period.
- Allergen immunotherapy (subcutaneous immunotherapy \[SCIT\]/sublingual immunotherapy \[SLIT\]) initiated within 6 months prior to screening, that is not on a stable dose (3 months prior to screening).
- Has received a biologic treatment approved for use in CRSwNP, asthma, or AD, even if administered to treat a different condition, within 4 months or 5 half-lives, whichever is longer, prior to screening.
- Have received treatment with any biologic or systemic immunosuppressants for inflammatory disease or autoimmune disease prior to the baseline visit:
- ... and 16 more (see full listing online)

## Locations (190 total)

---

AllerVie Clinical Research, Birmingham, Alabama, United States  
University of Alabama at Birmingham, Birmingham, Alabama, United States  
Keck Medicine of USC, Arcadia, California, United States  
... and 187 more locations

---

<https://clinicaltrials.gov/study/NCT06338995>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).